Prestige Consumer Healthcare Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 7/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 77.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Prestige Consumer Healthcare Inc's Score
Industry at a Glance
Industry Ranking
7 / 158
Overall Ranking
21 / 4562
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
6
analysts
Buy
Current Rating
77.500
Target Price
+28.50%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Prestige Consumer Healthcare Inc Highlights
StrengthsRisks
Prestige Consumer Healthcare Inc. is a consumer healthcare products company. The Company is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.
Fairly Valued
The company’s latest PE is 15.37, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 52.11M shares, decreasing 3.75% quarter-over-quarter.
Prestige Consumer Healthcare Inc. is a consumer healthcare products company. The Company is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.
Ticker SymbolPBH
CompanyPrestige Consumer Healthcare Inc
CEOLombardi (Ronald M)
Websitehttps://www.prestigebrands.com/
FAQs
What is the current price of Prestige Consumer Healthcare Inc (PBH)?
The current price of Prestige Consumer Healthcare Inc (PBH) is 62.855.
What is the symbol of Prestige Consumer Healthcare Inc?
The ticker symbol of Prestige Consumer Healthcare Inc is PBH.
What is the 52-week high of Prestige Consumer Healthcare Inc?
The 52-week high of Prestige Consumer Healthcare Inc is 90.040.
What is the 52-week low of Prestige Consumer Healthcare Inc?
The 52-week low of Prestige Consumer Healthcare Inc is 57.250.
What is the market capitalization of Prestige Consumer Healthcare Inc?
The market capitalization of Prestige Consumer Healthcare Inc is 3.02B.
What is the net income of Prestige Consumer Healthcare Inc?
The net income of Prestige Consumer Healthcare Inc is 214.60M.
Is Prestige Consumer Healthcare Inc (PBH) currently rated as Buy, Hold, or Sell?
According to analysts, Prestige Consumer Healthcare Inc (PBH) has an overall rating of Buy, with a price target of 77.500.
What is the Earnings Per Share (EPS TTM) of Prestige Consumer Healthcare Inc (PBH)?
The Earnings Per Share (EPS TTM) of Prestige Consumer Healthcare Inc (PBH) is 4.061.